Back to news

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire•12/11/2026•17:00 ET
0

Key Highlights

  • ➤Travere grants inducement RSUs covering 65,520 shares to 20 new employees
  • ➤RSUs vest over four years, with 25% vesting annually
  • ➤Grants qualify as employment inducements under Nasdaq Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in